Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02665650 · ClinicalTrials.gov registry record · Phase 1
Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
A Phase 1 study, sponsored by Affimed.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02665650 is a Phase 1 study that has completed, run by Affimed. The registered enrollment target is 30 participants.
The verdict
NCT02665650, a Phase 1 study, has completed, sponsored by Affimed.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to establish a dosing regimen for the combination therapy of AFM13 and pembrolizumab (MK-3475) in patients with relapsed or refractory (R/R) Hodgkin Lymphoma (HL) and to assess the safety and tolerability of this combination therapy.
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL AFM13
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-05 |
| Est. Completion | 2019-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02665650
The ClinicalTrials.gov registry entry for NCT02665650 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Affimed, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02665650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02665650 about?
NCT02665650 is a clinical study titled "Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma". The purpose of this study is to establish a dosing regimen for the combination therapy of AFM13 and pembrolizumab (MK-3475) in patients with relapsed or refractory (R/R) Hodgkin Lymphoma (HL) and to assess the safety and tolerability of this combination therapy.
What is the current status of trial NCT02665650?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2016-05. Estimated completion is 2019-03.
What interventions are being tested in trial NCT02665650?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), AFM13 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02665650?
This trial is sponsored by Affimed, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.